107392-72-3

Basic information

• Product Name: 5H-Pyrrolo[1,2-a]imidazole, 6,7-dihydro-2-phenyl-
• CAS NO: 107392-72-3
• Molecular Formula: C12H12N2
• Molecular Weight: 184.241
• Mol File: 107392-72-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5H-Pyrrolo[1,2-a]imidazole, 6,7-dihydro-2-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 5H-Pyrrolo[1,2-a]imidazole, 6,7-dihydro-2-phenyl-(107392-72-3)
• EPA Substance Registry System: 5H-Pyrrolo[1,2-a]imidazole, 6,7-dihydro-2-phenyl-(107392-72-3)

Safety Data

• Hazardous Substances Data: 107392-72-3(Hazardous Substances Data)

Usage

Structure

Heterocyclic aromatic ring structure with an imidazole core

Usage

Research and development of pharmaceuticals
Exploration as a serotonin receptor agonist
Investigated for potential use in anxiety, depression, and other psychological disorders
Potential applications in neuropharmacology
Tool for studying serotonin receptors and related pathways

Upstream product

• 7491-74-9 2-oxo-1-pyrrolidine acetamide 
• 91417-91-3 2-Chloro-5H,6,7-dihydropyrrolo<1,2-a>imidazole 
• 98-80-6 phenylboronic acid 
• 7544-75-4 2-iminopyrrolidine-hydrochloride 
• 70-11-1 α-bromoacetophenone 
• 876149-81-4 1-hydroxy-2-phenyl-perhydropyrrolo[1,2-a]imidazole 
• 42564-18-1 3-phenyl-6,7,8,8a-tetrahydro-4H-pyrrolo[1,2-e][1,2,5]oxadiazine 
• 42564-22-7 2-phenyl-5,6,7,7a-tetrahydro-3H-pyrrolo[2,1-a]imidazol-1-oxide 

Downstream Products

• 107392-82-5 3-bromo-2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 
• 883233-75-8 BrH*C₁₂H₁₁BrN₂ 

Relevant articles and documents

Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design

WDR5 is a chromatin-regulatory scaffold protein overexpressed in various cancers and a potential epigenetic drug target for the treatment of mixed-lineage leukemia. Here, we describe the discovery of potent and selective WDR5-WIN-site inhibitors using fragment-based methods and structure-based design. NMR-based screening of a large fragment library identified several chemically distinct hit series that bind to the WIN site within WDR5. Members of a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole fragment class were expanded using a structure-based design approach to arrive at lead compounds with dissociation constants 10 nM and micromolar cellular activity against an AML-leukemia cell line. These compounds represent starting points for the discovery of clinically useful WDR5 inhibitors for the treatment of cancer.

KINASE INHIBITORS

ABSTRACT The present invention provides kinase inhibitors of Formula I: .

BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KIANSE

-